Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Aubex Therapeutics General Information
Aubex Therapeutics has launched with a unique R&D program aimed at transforming treatment of solid tumor malignancies by modifying the tumor microenvironment to reduce fibrosis and enhance immune response. Early data show promise particularly in fibrotic cancers such as HER2+ and triple-negative breast cancers, pancreatic, esophageal SCC, colon, and NSCLC. The approach represents an innovative immuno-oncology strategy focusing on TME remodeling to improve patient outcomes.
Contact Information
Drug Pipeline
Pre-clinical
Key Partnerships
Aubex Therapeutics Funding
No funding data available
To view Aubex Therapeutics's complete valuation and funding history, request access »